Strategies for senolytic drug discovery
Aging Cell · 2023-10 · 22 (10)
DOI: 10.1111/acel.13948 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Aging Cell, online erschienen am 07.08.2023. Verfasst von Helen Power und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Engineering, School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Senotherapeutics, Antineoplastic Agents. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Senolytics are a category of drugs that reduce the impact of cellular senescence, an effect associated with a range of chronic and age‐related diseases. Since the discovery of the first senolytics in 2015, the number of known senolytic agents has grown dramatically. This review discusses the broad categories of known senolytics—kinase inhibitors, Bcl‐2 family protein inhibitors, naturally occurring polyphenols, heat shock protein inhibitors, BET family protein inhibitors, P53 stabilizers, repurposed anti‐cancer drugs, cardiac steroids, PPAR‐alpha agonists, and antibiotics. The approaches used to screen for new senolytics are articulated including a range of methods to induce senescence, different target cell types, various senolytic assays, and markers. The choice of methods can greatly influence the outcomes of a screen, with high‐quality screens featuring robust systems, adequate controls, and extensive validation in alternate assays. Recent advances in single‐cell analysis and computational methods for senolytic identification are also discussed. There is significant potential for further drug discovery, but this will require additional research into drug targets and mechanisms of actions and their subsequent rigorous evaluation in pre‐clinical models and human trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Engineering, School of Chemical and Biomolecular Engineering, The University of Sydney, Sydney, New South Wales, Australia.
- Centre for Advanced Food Engineering, The University of Sydney, Sydney, New South Wales, Australia.
- Bioengineering and Molecular Medicine Laboratory, The Children's Hospital at Westmead and The Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
ORCID-Profile: Helen Power, Aaron Schindeler
Zitieren
APA
Power, H., Valtchev, P., Dehghani, F., & Schindeler, A. (2023). Strategies for senolytic drug discovery. Aging Cell, 22(10). https://doi.org/10.1111/acel.13948
Vancouver
Power H, Valtchev P, Dehghani F, Schindeler A. Strategies for senolytic drug discovery. Aging Cell. 2023;22(10). doi:10.1111/acel.13948
BibTeX
@article{Power2023,
author = {Power, Helen and Valtchev, Peter and Dehghani, Fariba and Schindeler, Aaron},
title = {Strategies for senolytic drug discovery},
journal = {Aging Cell},
year = {2023},
volume = {22},
number = {10},
doi = {10.1111/acel.13948}
}
EUVIMED